Aspire Biopharma Holdings (ASBP) Other Non-Current Liabilities (2023 - 2025)
Aspire Biopharma Holdings (ASBP) posted quarterly Other Non-Current Liabilities of $40954.0 for Q4 2025, down 91.8% year-over-year from $499213.0 in Q4 2024, and down 97.98% quarter-over-quarter from $2.0 million in Q2 2025.
Aspire Biopharma Holdings (ASBP) Other Non-Current Liabilities (2023 - 2025) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has reported Other Non-Current Liabilities for 3 consecutive years, with $40954.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Other Non-Current Liabilities fell 91.8% year-over-year to $40954.0; the TTM figure through Dec 2025 stood at $40954.0 (down 91.8% YoY), while the FY2025 annual figure was $40954.0, down 91.8% from the prior year.
- Other Non-Current Liabilities eased to $40954.0 in Q4 2025 per ASBP's latest filing, from $2.0 million in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $2.0 million in Q2 2025 and bottomed at $40954.0 in Q4 2025.
- Historically, Other Non-Current Liabilities has averaged $743605.1 across 3 years, with a median of $450000.0 in 2024.
- On a YoY basis, Other Non-Current Liabilities climbed as much as 350.08% in 2025 and fell as far as 91.8% in 2025.
- Aspire Biopharma Holdings' Other Non-Current Liabilities stood at $155848.0 in 2023, then surged by 220.32% to $499213.0 in 2024, then slumped by 91.8% to $40954.0 in 2025.
- Business Quant data shows ASBP's Other Non-Current Liabilities at $40954.0 in Q4 2025, $2.0 million in Q2 2025, and $1.9 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Aspire Biopharma Holdings | 8.30 Mn | -3.86 Mn | -30,086.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 40,954.00 |
| Jun 30, 2025 | 2.03 Mn |
| Mar 31, 2025 | 1.88 Mn |
| Dec 31, 2024 | 499,213.00 |
| Sep 30, 2024 | 449,214.00 |
| Jun 30, 2024 | 450,000.00 |
| Mar 31, 2024 | 450,000.00 |
| Dec 31, 2023 | 155,848.00 |